ZA978455B - Use of leptin antagonists for treating insulin resistance in type II diabetes. - Google Patents

Use of leptin antagonists for treating insulin resistance in type II diabetes.

Info

Publication number
ZA978455B
ZA978455B ZA9708455A ZA978455A ZA978455B ZA 978455 B ZA978455 B ZA 978455B ZA 9708455 A ZA9708455 A ZA 9708455A ZA 978455 A ZA978455 A ZA 978455A ZA 978455 B ZA978455 B ZA 978455B
Authority
ZA
South Africa
Prior art keywords
diabetes
type
insulin resistance
treating insulin
leptin antagonists
Prior art date
Application number
ZA9708455A
Other languages
English (en)
Inventor
Guenter Mueller
Gerald Preibisch
Johann Ertl
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA978455B publication Critical patent/ZA978455B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA9708455A 1996-09-20 1997-09-19 Use of leptin antagonists for treating insulin resistance in type II diabetes. ZA978455B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19638487 1996-09-20

Publications (1)

Publication Number Publication Date
ZA978455B true ZA978455B (en) 1998-03-20

Family

ID=7806282

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9708455A ZA978455B (en) 1996-09-20 1997-09-19 Use of leptin antagonists for treating insulin resistance in type II diabetes.

Country Status (18)

Country Link
US (1) US6399745B1 (xx)
EP (1) EP0956302A1 (xx)
JP (1) JP2001500869A (xx)
KR (1) KR20010029537A (xx)
CN (1) CN1230966A (xx)
AR (1) AR008444A1 (xx)
AU (1) AU735178B2 (xx)
BR (1) BR9711513A (xx)
CA (1) CA2266585A1 (xx)
CZ (1) CZ90999A3 (xx)
HU (1) HUP9904023A3 (xx)
ID (1) ID21861A (xx)
IL (1) IL129057A0 (xx)
NO (1) NO991186D0 (xx)
PL (1) PL332458A1 (xx)
RU (1) RU2201249C2 (xx)
WO (1) WO1998012224A1 (xx)
ZA (1) ZA978455B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335107C (en) * 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
AU782230B2 (en) * 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2001090188A2 (en) 2000-05-22 2001-11-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Receptor-based interaction trap
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
EP2422807A3 (en) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7407929B2 (en) * 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
DE602005013811D1 (de) * 2004-11-01 2009-05-20 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
WO2007112069A2 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
MX2010005345A (es) * 2007-11-14 2010-08-31 Amylin Pharmaceuticals Inc Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
BR112013007388B1 (pt) 2010-09-28 2022-01-04 Amylin Pharmaceuticals, Llc Polipeptídeo tendo domínio de ligação de albumina e leptina, seu uso no tratamento de doenças, bem como composição farmacêutica que o compreende
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
CA2886393C (en) 2012-09-27 2019-02-26 The Children's Medical Center Corporation Pentacyclic triterpenes for the treatment of obesity
US20160375039A1 (en) 2013-11-26 2016-12-29 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN104829708B (zh) 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
PL3509624T3 (pl) 2016-09-12 2024-03-25 Amryt Pharmaceuticals Inc. Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie
EP3675961A1 (en) * 2017-08-31 2020-07-08 University Of Dundee Leptin peptides and their use for treating neurological disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) * 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
WO1997002004A2 (en) * 1995-06-30 1997-01-23 Eli Lilly And Company Methods for treating diabetes
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US5922678A (en) * 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
NO991186L (no) 1999-03-11
ID21861A (id) 1999-08-05
AU4458697A (en) 1998-04-14
EP0956302A1 (en) 1999-11-17
KR20010029537A (ko) 2001-04-06
US6399745B1 (en) 2002-06-04
PL332458A1 (en) 1999-09-13
WO1998012224A1 (en) 1998-03-26
BR9711513A (pt) 1999-08-24
AR008444A1 (es) 2000-01-19
NO991186D0 (no) 1999-03-11
CA2266585A1 (en) 1998-03-26
CZ90999A3 (cs) 1999-06-16
IL129057A0 (en) 2000-02-17
AU735178B2 (en) 2001-07-05
RU2201249C2 (ru) 2003-03-27
JP2001500869A (ja) 2001-01-23
CN1230966A (zh) 1999-10-06
HUP9904023A2 (hu) 2000-03-28
HUP9904023A3 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
ZA978455B (en) Use of leptin antagonists for treating insulin resistance in type II diabetes.
ZA979187B (en) Retractable needle and syringe combination.
AU4072799A (en) 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
HK1031174A1 (en) Compositions and methods for treating diabetes
CY2424B1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
PL344081A1 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
HK1018780A1 (en) 6-Phenylpyridine-2-ylamine derivatives, the composition and use thereof.
EP0879279A4 (en) DIABETE TREATMENT
ZA976812B (en) Method and composition for incorporating radiation-absorbing agents into polymers.
PL331901A1 (en) Syringe
PL331209A1 (en) Syringe
IL130082A0 (en) Dna encoding lepidopteran-active delta-endotoxins and its use
ZA985546B (en) Treatment of insulin resistance.
HK1020259A1 (en) Composition for use in the treatment and prevention of hyperuricemia.
ZA967513B (en) Method of treating insulin resistance.
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
AU1967897A (en) Method for treatment of insulin resistance
ZA200204374B (en) Pre-filled syringe and method for making same.
ZA971250B (en) Dental syringe.
ZA975906B (en) Syringes.
GB9820631D0 (en) Hair treatment composition, method and use
ZA979068B (en) Modified electrode material and its use.
HUP0000089A3 (en) Syringe
PL337220A1 (en) Application of leptin antagonists in treating diabetes
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method